Trial Profile

A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAY 3630914 (Primary) ; Pembrolizumab (Primary)
Indications Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Vividion Therapeutics

17 Mar 2025 Planned number of patients changed from 200 to 280.
18 Oct 2024 Planned number of patients changed from 160 to 200.
06 Feb 2024 According to Vividion Therapeutics media release, company announced that it has initiated dosing of patients in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com